Together, our results suggested that POSTN+ CAFs and SPP1+ macrophages were closely associated at the tumour stroma, which may be critical in inhibiting tumour immunity and promoting tumour progression, and targeting these cells may enhance the efficacies of ICI immunotherapies in NSCLC. The gene discussed is SPP1; the disease is non-small cell lung carcinoma.